AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12859476 — intervention group
Group type: COMPARATOR
Intervention: Control group (unfiltered plastic cannula)
Number of subjects: 120
Study 10190873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation therapy (90Sr/Y source train, 12, 14, or 16 Gy at 2 mm)
Number of subjects: 30
Study 10190873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation therapy
Number of subjects: 30
Study 8525689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine regimen with two injections four weeks apart
Number of subjects: 757
Study 8525689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine regimen with two injections eight weeks apart
Number of subjects: 757
Study 2407162 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement and wound care
Number of subjects: 163
Study 2407162 — intervention group
Group type: COMPARATOR
Intervention: Wound care alone
Number of subjects: 163
Study 7387147 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 26
Study 7387147 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)
Number of subjects: 26
Study 31960719 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group with both epidural blockade and parecoxib
Number of subjects: 186
Study 31960719 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade group
Number of subjects: 186
Study 31960719 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study 31813359 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A plus evidence‐based movement training
Number of subjects: 140
Study 31813359 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin‐A plus handout of exercises
Number of subjects: 140
Study 28527615 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch technique (T)
Number of subjects: 300
Study 28527615 — intervention group
Group type: COMPARATOR
Intervention: No-touch technique (NT)
Number of subjects: 300
Study 28527615 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch technique (T) after crossover
Number of subjects: 300
Study 28527615 — intervention group
Group type: COMPARATOR
Intervention: No-touch technique (NT) after crossover
Number of subjects: 300
Study 28198091 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month DAPT
Number of subjects: 604
Study 28198091 — intervention group
Group type: COMPARATOR
Intervention: 6-month DAPT
Number of subjects: 604
Study 25637334 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-and-reach (UR)
Number of subjects: 42
Study 25637334 — intervention group
Group type: COMPARATOR
Intervention: Forward reach (FR)
Number of subjects: 42
Study 23026132 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in the leptin gene (17 SNPs)
Number of subjects: 609
Study 23026132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 609
Study 23026132 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis combining MARS, GENDEP, and STAR(⁎)D studies
Number of subjects: 609
Study 23026132 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin mRNA expression and serum levels
Number of subjects: 609
Study 20889289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation protocol
Number of subjects: 21
Study 20889289 — intervention group
Group type: COMPARATOR
Intervention: Sedation protocol with daily sedative/analgesic interruption
Number of subjects: 21
Study 18178380 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg/d)
Number of subjects: 17
Study 18178380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18178380 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose (2000 mg/d)
Number of subjects: 17
Study 16918591 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) 1700 mg/day
Number of subjects: 20
Study 16918591 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (T) 600 mg/day
Number of subjects: 20
Study 16036074 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly potent bisphosphonates
Number of subjects: 0
Study 10932487 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-1 and IGFBP-3 concentrations in GHD children
Number of subjects: 60
Study 10932487 — intervention group
Group type: COMPARATOR
Intervention: Serum IGF-1 and IGFBP-3 concentrations in NVSS children
Number of subjects: 60
Study 10932487 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1 and IGFBP-3 levels transformed to standard deviation score (SDS)
Number of subjects: 60
Study 10932487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of IGF-1 and IGFBP-3 < -2 SDS
Number of subjects: 60
Study 8775106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 500
Study 8775106 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 500
Study 1619587 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent heart rate biofeedback
Number of subjects: 32
Study 1619587 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contingent feedback (decreased heart rate)
Number of subjects: 32
Study 1619587 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition mentioned
Number of subjects: 32
Study 1619587 — intervention group
Group type: COMPARATOR
Intervention: No competitive instructions
Number of subjects: 32
Study 6377492 — intervention group
Group type: EXPERIMENTAL
Intervention: Indotard 50 mg given twice daily
Number of subjects: 30
Study 6377492 — intervention group
Group type: COMPARATOR
Intervention: Indocid 25 mg given four times daily
Number of subjects: 30
Study 6377492 — intervention group
Group type: EXPERIMENTAL
Intervention: Indotard (younger patients)
Number of subjects: 30
Study 6377492 — intervention group
Group type: COMPARATOR
Intervention: Indocid (older patients)
Number of subjects: 30
Study 31364474 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth+SMS
Number of subjects: 44
Study 31364474 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 44
Study 31364474 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 44
Study 30016391 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiotherapy (I-CCRT)
Number of subjects: 479
Study 30016391 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 479
Study 27297843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor without GPI
Number of subjects: 19824
Study 27297843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor with GPI
Number of subjects: 19824
Study 27297843 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 19824
Study 25101534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - 10 sessions, 830 nm, 50 mW output power, 707 J/cm² fluence; L group, n=23
Number of subjects: 43
Study 25101534 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment - 10 sessions; P group, n=20
Number of subjects: 43
Study 23350191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergoferon
Number of subjects: 213
Study 23350191 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (150 mg daily for 5 days)
Number of subjects: 213
Study 23350191 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 213
Study 23350191 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 213
Study 20507198 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (home televisits with nurse and dietitian educators every 4‐6 weeks for 2‐6 years)
Number of subjects: 610
Study 20507198 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (home televisits)
Number of subjects: 610
Study 18656868 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris Hip Score
Number of subjects: 222
Study 18656868 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index
Number of subjects: 222
Study 18656868 — intervention group
Group type: EXPERIMENTAL
Intervention: Eq‐5d index score
Number of subjects: 222
Study 18656868 — intervention group
Group type: EXPERIMENTAL
Intervention: Eq‐5d visual analogue scale
Number of subjects: 222
Study 15918196 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg
Number of subjects: 134
Study 15918196 — intervention group
Group type: COMPARATOR
Intervention: esomeprazole 20 mg
Number of subjects: 134
Study 12514155 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐Classic (LMA‐C) or LMA‐ProSeal (PLMA)
Number of subjects: 209
Study 12514155 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 209
Study 12514155 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐C or PLMA
Number of subjects: 209
Study 12514155 — intervention group
Group type: COMPARATOR
Intervention: ETT
Number of subjects: 209
Study 12145072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg initial loading dose for 10 min; maintenance, 0.4‐0.7 microg. kg(‐1). h(‐1))
Number of subjects: 40
Study 12145072 — intervention group
Group type: COMPARATOR
Intervention: Propofol (75 microg. kg(‐1). min(‐1) x 10 min; maintenance, 12.5‐75 microg. kg(‐1). min(‐1))
Number of subjects: 40
Study 12145072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 10335872 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF plus filgrastim
Number of subjects: 0
Study 10335872 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim alone
Number of subjects: 0
Study 7780060 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulphone membranes
Number of subjects: 0
Study 7780060 — intervention group
Group type: COMPARATOR
Intervention: Low-flux cellulose-based membranes
Number of subjects: 0
Study 2081012 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed group (received letter about high blood pressure)
Number of subjects: 29
Study 2081012 — intervention group
Group type: COMPARATOR
Intervention: Control group (received neutral letter)
Number of subjects: 29
Study 6988174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol
Number of subjects: 15
Study 6988174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31888939 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + app + web
Number of subjects: 250
Study 31888939 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 250
Study 26641648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 μg/kg/h)
Number of subjects: 150
Study 26641648 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride)
Number of subjects: 150
Study 26402337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 102
Study 26402337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 24045792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling advocating choice of foods to increase unsaturated FA intake and reduce saturated FA intake.
Number of subjects: 90
Study 24045792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling).
Number of subjects: 90
Study 21159327 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal worry
Number of subjects: 0
Study 21159327 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-based worry
Number of subjects: 0
Study 21159327 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-worriers)
Number of subjects: 0
Study 19433392 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy for breast cancer
Number of subjects: 251
Study 18028772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber dressing
Number of subjects: 120
Study 18028772 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nanoparticle dressing
Number of subjects: 120
Study 18028772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel dressing
Number of subjects: 120
Study 18028772 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze
Number of subjects: 120
Study 14998841 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperMIP (mitomycin C 6 mg/m2; ifosfamide 4.5 g/m2; cisplatin 60 mg/m2; carboplatine 200 mg/m2)
Number of subjects: 351
Study 14998841 — intervention group
Group type: COMPARATOR
Intervention: MIP (mitomycin C 6 mg/m2; ifosfamide 3 g/m2; cisplatin 50 mg/m2)
Number of subjects: 351
Study 14998841 — intervention group
Group type: COMPARATOR
Intervention: MIP
Number of subjects: 351
Study 14998841 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperMIP
Number of subjects: 351
Study 14998841 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP and SuperMIP
Number of subjects: 351
Study 11489064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide
Number of subjects: 50
Study 11489064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 50
Study 11489064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide plus bumetanide
Number of subjects: 50
Study 11489064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9721778 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal suppositories alone
Number of subjects: 175
Study 9721778 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 plus Laminaria
Number of subjects: 175
Study 9721778 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 plus Laminaria plus gel
Number of subjects: 175
Study 8151058 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with 13.2 micrograms Fel d I antigen
Number of subjects: 28
Study 3049213 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of nitrofurantoin
Number of subjects: 69
Study 3049213 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of furazolidone
Number of subjects: 69
Study 3049213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31549416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachment
Number of subjects: 18
Study 31549416 — intervention group
Group type: EXPERIMENTAL
Intervention: Equator attachment
Number of subjects: 18
Study 31549416 — intervention group
Group type: COMPARATOR
Intervention: Both attachments
Number of subjects: 18
Study 31549416 — intervention group
Group type: COMPARATOR
Intervention: Patient preference for retention system
Number of subjects: 18
Study 27560256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program (5 education sessions over 7 months)
Number of subjects: 57
Study 27560256 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled abnormal glucose metabolism (AGM) among pre-diagnosed diabetic cases
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase by one year
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Retired status
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight status
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-drinker status
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (Stage I)
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (Stage II)
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed status
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Business-owner status
Number of subjects: 269
Study 27755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smoker status
Number of subjects: 269
Study 25447748 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal cure (spa treatment including underwater shower, massage-jet showers, hydromassage, pool rehabilitation, and peloid therapy)
Number of subjects: 240
Study 25447748 — intervention group
Group type: COMPARATOR
Intervention: Non-thermal rehabilitation (analgesic physiotherapy, muscle strengthening, and group physical rehabilitation)
Number of subjects: 240
Study 25447748 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison at day 21
Number of subjects: 240
Study 25447748 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison at 12 months
Number of subjects: 240
Study 22077475 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful life events
Number of subjects: 160
Study 22077475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stressors
Number of subjects: 160
Study 22077475 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stressors
Number of subjects: 160
Study 22077475 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress severity
Number of subjects: 160
Study 20408861 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NTHi treatment
Number of subjects: 64
Study 20408861 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 64
Study 18202420 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase rinses (5 mL of 5,000 U/mL) three times weekly
Number of subjects: 0
Study 18202420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) three times weekly
Number of subjects: 0
Study 16578941 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant, intercessory prayer
Number of subjects: 15
Study 15215700 — intervention group
Group type: EXPERIMENTAL
Intervention: Douching after menses
Number of subjects: 250
Study 11056121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop protocol (GnRHa administration stopped with the onset of menses, high doses of gonadotrophins)
Number of subjects: 70
Study 11056121 — intervention group
Group type: COMPARATOR
Intervention: Non-stop protocol (long GnRHa suppression with high doses of gonadotrophins)
Number of subjects: 70
Study 11056121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop protocol
Number of subjects: 70
Study 11056121 — intervention group
Group type: COMPARATOR
Intervention: Non-stop protocol
Number of subjects: 70
Study 8937948 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (AD) alone
Number of subjects: 12
Study 8937948 — intervention group
Group type: EXPERIMENTAL
Intervention: AD plus Continuous Quality Improvement (CQI)
Number of subjects: 12
Study 8937948 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12
Study 1546821 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI only
Number of subjects: 123
Study 1546821 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with spacer
Number of subjects: 123
Study 1546821 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 123
Study 1546821 — intervention group
Group type: COMPARATOR
Intervention: MDI with spacer and Turbuhaler
Number of subjects: 123
Study 3987071 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (15 mg infusion)
Number of subjects: 7
Study 3987071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally)
Number of subjects: 7
Study 3987071 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (30 mg infusion)
Number of subjects: 7
Study 2906946 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training and imaginal exposure to vitamin consumption followed by in vivo exposure to vitamin taking
Number of subjects: 0
Study 2906946 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure to aspirin and placebo capsules
Number of subjects: 0
Study 2906946 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization of treatment effects
Number of subjects: 0
Study 2906946 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at three and six months
Number of subjects: 0
Study 2906946 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysiological assessment data
Number of subjects: 0
Study 30418164 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy DES
Number of subjects: 24
Study 28697117 — intervention group
Group type: EXPERIMENTAL
Intervention: Video colposcopy
Number of subjects: 225
Study 28697117 — intervention group
Group type: COMPARATOR
Intervention: No video colposcopy
Number of subjects: 225
Study 26153198 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention package at baseline and three months
Number of subjects: 640
Study 22773233 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-coated lightweight mesh
Number of subjects: 102
Study 22773233 — intervention group
Group type: COMPARATOR
Intervention: Medium-weight composite mesh
Number of subjects: 102
Study 22773233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 21210608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid clinical experiences (part simulation and part traditional clinical)
Number of subjects: 0
Study 21210608 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical experiences
Number of subjects: 0
Study 19229804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical compression therapy followed by a compression bandage (302 patients, group 1)
Number of subjects: 908
Study 19229804 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression with application of a calcium ion releasing device (303 patients; group 2)
Number of subjects: 908
Study 19229804 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression with a thrombin covered PAD without compression bandage (303 patients, group 3)
Number of subjects: 908
Study 16498158 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 83
Study 16498158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 11753130 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy
Number of subjects: 0
Study 11753130 — intervention group
Group type: COMPARATOR
Intervention: Medical management (phytotherapy, alpha‐blockers, 5 alpha‐reductase inhibitors)
Number of subjects: 0
Study 11753130 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 0
Study 10091954 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate 2 g daily for 7 days
Number of subjects: 12